News

The Cleveland Neurodesign Entrepreneurs Workshop, a novel program dedicated to cultivating entrepreneurship in neurotechnology, reached a major milestone earlier this month when it welcomed its 200th student. Modeled on the Stanford Biodesign framework but tailored to the unique challenges of neurotech commercialization, CNEW continues to serve as a launchpad for the next generation of innovators.

By now, most professionals in the neuromodulation industry have become aware of some of the negative news reports and journal articles calling into question the value of spinal cord stimulation for treating back pain. The SCS industry has fought back on a number of fronts and continues to offer product enhancements and sponsor clinical trials that can produce the scientific evidence necessary to convince patients, payers, and regulators that the therapy is effective and appropriate.

In recent years, neuroengineers have devised a number of new modalities for interfacing with the nervous system. Among these are optical stimulation, vibrational stimulation, and optogenetics. A newer and perhaps more promising technology is sonogenetics. Sonogenetics, the use of focused ultrasound to control cells that have been made ultrasound-responsive via gene delivery, is moving from compelling papers to a potential platform strategy.

OSA is a serious health condition affecting an estimated 23 million people in the U.S. If left untreated, it significantly increases the risk of cardiovascular and neurological diseases. The standard treatment is Continuous Positive Airway Pressure, but its effectiveness is limited , with only about 40% of users sticking with the therapy long-term. For patients who cannot tolerate CPAP, surgical options are available.

The 7th Annual Meeting of the American Society of Pain and Neuroscience, held July 16–20, 2025, at the Fontainebleau Miami Beach, brought together more than 4,100 attendees—roughly half healthcare professionals. As ASPN continues to grow in influence and reach, this year’s event emphasized its core mission: improving education, elevating young professionals, and embracing innovation through disruption.

In previous issues of this publication, we’ve highlighted some of the negative impacts on the neurotechnology industry from the new administration in Washington, DC. Many of these have related to funding cuts for critical research and staffing cuts for key government agencies and programs. But in case these impacts were not enough, neuromodulation vendors now find themselves under the eight ball for reimbursement decisions.

On July 15, 2025, The Centers for Medicare & Medicaid Services issued a draft rule that aims to create a level playing field for hospitals and ambulatory surgical centers. CMS believes that advancements in medical technology, surgical techniques, and recovery protocols have nearly eliminated the need for recovery times exceeding 24 hours, which defines inpatient care. Consequently, CMS plans to shift all 1,731 inpatient procedures to outpatient settings with recovery times under 24 hours between 2026 and 2028.

The neurotechnology market for stroke rehabilitation suffered a serious setback in 2008 when Northstar Neuroscience, the Seattle, WA developer of cortical stimulation systems, failed its EVEREST trial, which led to the demise of the firm a year later. The company’s therapeutic approach relied on epidural cortical stimulation to promote neuroplasticity to improve motor function, For nearly a decade…

Neural engineers, clinicians, and neuroscientists assembled in Arlington, VA last month for the 2025 Neural Interfaces Conference. The three-day event is the outgrowth of the NIH Neural Prosthesis Workshop, which began as an annual gathering of researchers funded Program. This year’s conference was produced Society. The sessions offered a look back at key events from the conference’s history as well as a look forward toward new developments in the field.

For two days this June, the corridors of imec’s headquarters in Leuven, Belgium thrummed with a new kind of energy. The inaugural European edition of the Neurotech Leaders Forum—long a staple in the U.S.—brought together a dynamic mix of entrepreneurs, investors, academics, and strategists to spotlight Europe’s accelerating neurotechnology ecosystem. Co-hosted , the forum provided a panoramic view…